Novo Nordisk Shares Plunge on Insulin's FDA Failure
Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."
Most Recent Videos
Trump Trade: Does the Rally Have Legs?
27:07 - Jingyi Pan, markets strategist at IG Asia, discusses the Trump reflation trade, momentum in the markets and her outlook for gold. She speaks to Bloomberg's Haidi Lun on "Bloomberg Markets." (Source: Bloomberg)